Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

Decompensated Heart Failure Clinical Trial

Official title:

Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03440970
• Other study ID #: 2000022016
• Secondary ID: 1R01HL139629-01
• Status: Recruiting
• Phase: Early Phase 1
• Start date: January 15, 2019
• Est. completion date: June 2025

Study information

• Verified date: June 2024
• Source: Yale University
• Contact: Katherine Keith
• Phone: 8602273925
• Email: katherine.keith[@]yale.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to investigate the quantitative effects of sodium-free chloride supplementation on electrolyte balance, volume status, and sodium avidity in stable heart failure patients in a highly controlled environment.

Description:

The overarching goal of this study is to develop a comprehensive understanding of the biology and therapeutic potential of sodium-free chloride supplementation. While sodium homeostasis has been the focus of substantial investigation, very little research has been devoted to understanding chloride homeostasis. Thus, this proposal is designed to obtain the full spectrum of information pertaining to chloride, such as novel areas with great interest by the scientific community (i.e. modulation of the WNK-kinase system and the use of exosomes), to more practical/basic questions (i.e. what happens to sodium chloride balance when a patient is challenged with chloride).

This study is designed as a highly controlled inpatient "GCRC" arm to be compared to a real world efficacy study that has been proposed as a separate study. With extensive biobanking and analysis of samples in the inpatient setting, we will be able to deliver a great wealth of information on the biology and therapeutic potential of manipulating chloride homeostasis in heart failure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meticulous history of medical compliance and attendance of appointments

• Stable heart failure as defined by:

1. Absence of hospitalizations for 90 days

2. Stable diuretic and medical therapy for 30 days

3. Opinion of the patient's treating physician (Heart Failure Cardiologist) that the patient is at optimal volume status

• Evidence based heart failure treatment with maximally-tolerated doses of a beta blocker, ACE/ARB/neprilysin inhibitor and aldosterone antagonist

• Ejection fraction <40%

• Chronic loop diuretic therapy with = 40 mg of furosemide equivalents

• Serum chloride <102 mmol/L

Exclusion Criteria:

• Inability to commit to or comply with the rigorous outpatient or inpatient study protocol

• Use of a thiazide diuretic in the last 30 days

• History of metabolic or respiratory acidosis

• Use of metformin, acetazolamide, or any other agent that could predispose to acidosis. Patients who are on metformin may be enrolled if their metformin can be safely discontinued for the inpatient randomized periods in each arm. Any participants who have consistently elevated Blood glucose readings > 200 mg/dL while inpatient will not be enrolled.

• Serum bicarbonate level <24mmol/L

• Estimated glomerular filtration rate <30 mL/min or prior or current history of renal replacement therapy

• Anemia, as defined by Hemoglobin <8.0 g/dL at screening visit

• Urinary incontinence or significant bladder dysfunction (post-void residual at screening >100 mL

• Use of chloride containing medications that provide more than 5 mmol/day of chloride if the medication cannot be discontinued or substituted

• Appears unlikely, or unable to participate in the required study procedures, as assessed by the study PI or research RN (ex: clinically-significant psychiatric, addictive, or neurological disease)

• Inability to give written informed consent or follow study protocol

Related Conditions & MeSH terms

• Decompensated Heart Failure
• Heart Failure

Intervention

Drug:
• Lysine Chloride
Patients will receive the study drug twice a day for 5 days.

Other:
• Placebo
Patients will receive the placebo twice a day for 5 days.

Locations

Country	Name	City	State
United States	Yale University	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Blood Volume	Volumex is albumin labeled with the iodine isotope I-131 and is an FDA-approved method used to determine total blood volume. A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of blood collection will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days
Secondary	Change in log NTpro-BNP	N-terminal prohormone of brain natriuretic peptide (NTpro-BNP) is used to screen and diagnosis of acute congestive heart failure (CHF) and can be used to establish prognosis in heart failure. A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of NTpro-BNP will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days
Secondary	Change in Serum Creatinine	A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of serum creatinine will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days
Secondary	Change in Cystatin C	A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of cystatin C will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days
Secondary	Change in Chloride	A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of chloride will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days
Secondary	Change in Bicarbonate	A linear mixed effect model will be used to analyze the trial with class variables of time and treatment group. Daily measures of bicarbonate will be compared across the 7 day collection period between intervention and placebo arms.	Daily for 7-days